Chiasma Company Profile (NASDAQ:CHMA)

About Chiasma (NASDAQ:CHMA)

Chiasma logoChiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CHMA
  • CUSIP: N/A
  • Web:
  • Market Cap: $60.9 million
  • Outstanding Shares: 24,359,000
Average Prices:
  • 50 Day Moving Avg: $2.52
  • 200 Day Moving Avg: $2.52
  • 52 Week Range: $1.55 - $2.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.75
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.04 per share
  • Price / Book: 0.82
  • EBITDA: ($29,420,000.00)
  • Return on Equity: -35.96%
  • Return on Assets: -31.97%
  • Current Ratio: 10.40%
  • Quick Ratio: 10.40%
  • Average Volume: 78,720 shs.
  • Beta: 1.38
  • Short Ratio: 18.76

Frequently Asked Questions for Chiasma (NASDAQ:CHMA)

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How were Chiasma's earnings last quarter?

Chiasma, Inc. (NASDAQ:CHMA) released its quarterly earnings data on Friday, May, 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.06. View Chiasma's Earnings History.

When will Chiasma make its next earnings announcement?

Chiasma is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Chiasma.

Are investors shorting Chiasma?

Chiasma saw a decrease in short interest during the month of September. As of September 29th, there was short interest totalling 442,548 shares, a decrease of 35.1% from the September 15th total of 681,631 shares. Based on an average trading volume of 85,511 shares, the days-to-cover ratio is currently 5.2 days. Approximately 3.7% of the shares of the stock are short sold.

Who are some of Chiasma's key competitors?

Who are Chiasma's key executives?

Chiasma's management team includes the folowing people:

  • David M. Stack, Independent Chairman of the Board
  • Mark J. Fitzpatrick, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
  • Drew Enamait, Principal Accounting Officer, Vice President - Finance & Administration, Corporate Controller
  • Roni Mamluk Ph.D., Director
  • Todd Foley, Independent Director
  • Bard J. Geesaman M.D. Ph.D., Independent Director
  • Scott Minick, Independent Director
  • John A. Scarlett M.D., Independent Director

When did Chiasma IPO?

(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

How do I buy Chiasma stock?

Shares of Chiasma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chiasma's stock price today?

One share of Chiasma stock can currently be purchased for approximately $2.50.

MarketBeat Community Rating for Chiasma (NASDAQ CHMA)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  185
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Chiasma (NASDAQ:CHMA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: N/A
Consensus Price Target History for Chiasma (NASDAQ:CHMA)
Price Target History for Chiasma (NASDAQ:CHMA)
Analysts' Ratings History for Chiasma (NASDAQ:CHMA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/17/2017Barclays PLCDowngradeEqual Weight -> UnderweightN/AView Rating Details
5/13/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
4/18/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$43.00 -> $9.00N/AView Rating Details
4/18/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Chiasma (NASDAQ:CHMA)
Earnings by Quarter for Chiasma (NASDAQ:CHMA)
Earnings History by Quarter for Chiasma (NASDAQ CHMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.22)N/AView Earnings Details
5/5/2017Q1 2017($0.23)($0.29)ViewN/AView Earnings Details
8/10/2016Q2($0.63)($0.83)ViewListenView Earnings Details
5/11/2016Q1($0.63)($0.71)ViewListenView Earnings Details
3/14/2016Q4($0.53)($0.61)ViewListenView Earnings Details
11/12/2015Q315($0.38)($0.46)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Chiasma (NASDAQ:CHMA)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-1.43 EPS


Dividend History for Chiasma (NASDAQ:CHMA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Chiasma (NASDAQ:CHMA)
Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 50.40%
Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)
Institutional Ownership by Quarter for Chiasma (NASDAQ:CHMA)
Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2017Scott MinickDirectorBuy25,000$2.37$59,250.00View SEC Filing  
9/20/2017Scott MinickDirectorBuy15,000$2.38$35,700.00View SEC Filing  
7/21/2015Health Ventures Lp 7-MedMajor ShareholderBuy93,750$16.00$1,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Chiasma (NASDAQ:CHMA)
Latest Headlines for Chiasma (NASDAQ:CHMA)
Loading headlines, please wait.



Chiasma (CHMA) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.